Bupropion and Breastfeeding
Bupropion can be used during breastfeeding with caution, as infant exposure is minimal (approximately 2% of maternal weight-adjusted dose), but close monitoring for seizures is essential due to two case reports of seizures in breastfed infants. 1, 2
Compatibility Assessment
Bupropion is present in human milk along with its active metabolites, though at very low levels that are sometimes undetectable in infant serum 1. The most recent 2024 ADHD guideline from the American Journal of Obstetrics and Gynecology classifies bupropion during breastfeeding as "caution is advised" based on very limited data (21 cases) 1.
Key Safety Data
Infant Exposure:
- Average daily infant exposure is 2% of the maternal weight-adjusted dose (assuming 150 mL/kg daily milk consumption) 2
- Bupropion and metabolites have been detected in breast milk but often at undetectable levels in infant serum 3, 4
- The relative infant dose is well below the 10% safety threshold typically used for medication compatibility 3
Critical Safety Concern:
- Two postmarketing case reports documented seizures in breastfed infants exposed to bupropion 1, 2, 5
- The relationship between bupropion exposure and these seizures remains unclear, but the seizure risk cannot be dismissed 2
- One detailed case involved a 6.5-month-old with seizure-like symptoms and emesis while exposed to both bupropion and escitalopram, with symptoms resolving after discontinuation 5
Dosing for Lactating Mothers
Standard adult dosing applies (no dose adjustment needed specifically for lactation):
Sustained-Release (SR):
- Starting dose: 100-150 mg PO daily
- Maintenance dose: 100-150 mg PO twice daily 1
Extended-Release (XL):
- Starting dose: 150 mg PO daily
- Maintenance dose: 150-300 mg PO daily
- Maximum dose: 450 mg per day 1
Clinical Decision Algorithm
Step 1: Risk-Benefit Assessment
- Evaluate severity of maternal condition (depression, smoking cessation need)
- Consider alternative medications with more robust lactation safety data
- If bupropion is clinically necessary and alternatives are inadequate, proceed with monitoring plan
Step 2: Informed Consent
- Discuss the limited data (only 21 published cases)
- Explicitly warn about the two seizure case reports
- Document that while generally no adverse events are reported, serious outcomes have occurred
Step 3: Monitoring Protocol
- Mandatory infant monitoring for:
- Seizure activity (any abnormal movements, staring spells, rhythmic jerking)
- Excessive sedation or lethargy
- Poor feeding or irritability
- Any neurological symptoms
- Schedule close follow-up visits in first 2-4 weeks
- Instruct mother to seek immediate medical attention if any concerning symptoms develop
Step 4: Minimize Infant Exposure
- Use the lowest effective maternal dose
- Consider timing breastfeeding just before maternal dose to minimize peak milk concentrations
- If seizures or concerning symptoms occur, immediately discontinue breastfeeding and evaluate infant
Important Caveats
Pharmacokinetic Considerations:
- Milk-to-plasma ratios range from 2.51 to 8.58, indicating significant accumulation in breast milk 6
- However, infant plasma levels are typically undetectable despite milk presence 6, 4
- Bupropion has active metabolites (hydroxybupropion, erythrohydrobupropion, threohydrobupropion) that also transfer to milk 3, 6
Drug Interactions:
- The seizure case involving combined bupropion and escitalopram suggests potential increased risk with polytherapy 5
- Bupropion inhibits CYP2D6, which may affect metabolism of other medications
- Avoid combining with other medications that lower seizure threshold
Contraindications to Consider:
- Infant with seizure disorder or family history of seizures
- Premature or medically fragile infants
- Maternal use of multiple CNS-active medications
FDA Labeling Guidance
The FDA label explicitly states: "The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for bupropion and any potential adverse effects on the breastfed child" 2. The label acknowledges that postmarketing reports have described seizures in breastfed infants, though the relationship remains unclear 2.
Human milk concentrations show bupropion and metabolites are present, with average infant exposure of 2% of maternal dose 2. The FDA does not contraindicate breastfeeding but emphasizes careful consideration of risks versus benefits 2.